Navigation Links
Stanford-StartX Fund-Backed Nirmidas Biotech Raises $2 Million for Diagnostic Research Tools
Date:8/18/2014

Palo Alto, CA (PRWEB) August 18, 2014

Nirmidas Biotech, Inc., a diagnostic research technology company, is announcing that it has raised $2 million in seed round funding to commercialize its fluorescence enhancing plasmonic gold technology, called “pGOLD.” The technology platform, which significantly boosts the ability to detect disease biomarkers, is based on nearly a decade of research at Stanford University and is showing great promise as a diagnostic research tool in the life science and pharmaceutical fields. Nirmidas investors include a prominent VC firm, a life science angel investor, and the Stanford-StartX Fund.

With pGOLD technology, afflictions such as cancer, auto-immune disorders, cardiovascular disease, and diabetes can be detected at earlier stages and with better accuracy by creating non-invasive, point-of-care testing. Early detection could significantly change the nature and cost of patient care.

Dr. Hongjie Dai, the scientific co-founder of Nirmidas Biotech and Chaired Professor of Chemistry at Stanford, has published several academic papers about the technology. Dr. Dai’s passion for pGOLD’s potential to improve early detection outcomes and patient care led him develop market opportunities for his discoveries.

“Fluorescence is broadly used in diagnostic testing and biological research. Our signal enhancing technology simply makes it easier to see and detect various debilitating medical issues and diseases at the earliest stage possible. We believe it can be a real life saver,” said Dr. Hongjie Dai, Co-founder of Nirmidas Biotech.

The core of the pGOLD technology platform consists of an ultra-thin, film-like fluorescence enhancing plasmonic gold coating and its proprietary application technique. pGOLD Chips and pGOLD Beads came to market in mid-March. The products offer near-infrared fluorescence signal enhancement over 100-fold. This enables increased sensitivity, higher signal to noise ratio, high degree of multiplexing, and improved specificity, potentially leading to more rapid and accurate early-stage disease diagnoses incorporated into wearable healthcare, a market that is estimated to eventually be in excess of $2 billion dollars.

“The early adopters have been very satisfied with how pGOLD Chips and pGOLD Beads address their immediate research needs. We’ve surpassed their expectations and inspired them to envision the boundless product extensions and applications,” said Dr. Meijie Tang, CEO and Co-founder of Nirmidas Biotech.

As featured in prominent publications such as Nature Medicine and Nature Communications, pGOLD Chips and pGOLD Beads are now being commercialized by Nirmidas for the research community, the pharmaceutical community and other life science companies, as well as for in vitro diagnostic companies.

About Nirmidas Biotech, Inc.

Nirmidas Biotech, Inc., provides solutions for bio-analytical and diagnostic researchers using plasmonic gold (pGOLD) technology that vastly enhances near-infrared fluorescence signal, optimized over nearly a decade of research. Stanford Chaired Professor Dr. Hongjie Dai, a renowned nanotechnology expert, and Dr. Meijie Tang founded the Palo Alto-based company in 2013 with a vision for crafting innovative solutions to improve human life quality by developing breakthrough products at the intersection of life science research, in vitro diagnosis, and digital healthcare. Nirmidas is a resident at Janssen Labs @QB3 as well as StartX Med, a Stanford-affiliated nonprofit technology accelerator program. For more information, please visit: http://www.nirmidas.com.

About StartX

StartX is a 501(c)(3) Stanford-affiliated nonprofit in Silicon Valley that runs one of the world’s top startup accelerator programs. Our mission is to advance the development of the best entrepreneurs through experiential education and collective intelligence. Since launching in 2010, we have supported more than 160 companies and 370 entrepreneurs across a wide spectrum of industries. StartX and StartX Med, dedicated to medical and biotechnology, provides founders with access to a powerful network of entrepreneurs, investors, mentors, and industry partners, along with office space and a variety of other resources. We are supported by Stanford University, Stanford Hospital & Clinics, Kauffman Foundation, Microsoft, Steelcase, Intuit, Blackstone Charitable Foundation, Greylock Partners, Draper Fisher Jurvetson, Sequoia Capital, Merck, Genentech, Johnson & Johnson and many others. For more information, visit http://startx.stanford.edu.

Read the full story at http://www.prweb.com/releases/nirmidas/seedfunding/prweb12100864.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
2. Pharma and Biotech Consulting Firm Announces New Website, Expanded Services
3. Registration Opens for the 2013 BioTechniques Virtual Symposium—Exploring the Modern Lab
4. Second annual Brain Tumor Biotech Summit 2013 at Weill Cornell
5. Biotechnology Market Is Expected to Reach USD 414.5 billion in 2017 : Transparency Market Research
6. New Biotechnology Report: Regenerative Medicine Markets
7. Cattle flatulence doesnt stink with biotechnology
8. Ganeden Biotech Hits IFT Annual Conference
9. Nanobiotechnology Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
10. U.S. Environmental Biotechnology Product Market: 2018 Forecasts and Analysis Research Report Now Available at ReportsnReports.com
11. Ganeden Biotech® Invests in Consumer Education with Its New GanedenBC30® Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to ... students from U.S. universities who will draw from Siemens’ deep knowledge of ...
(Date:2/12/2016)... ... 2016 , ... Each year, the American Physical Therapy Association (APTA) offers a ... Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to attend ... about their chosen field and network with their colleagues. As in years past, ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... AssureVest Insurance Group, ... is initiating a charity drive that will raise funds earmarked to purchase computers and ... Tayloe Elementary School. , “My school is in a low-income area and has more ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, a full ... of the latest charity campaign in their community enrichment program. Art Expression utilizes ... worthy cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... ALISO VIEJO, Calif. , Feb. 12, 2016 /PRNewswire/ ... patient enrollment in a study to evaluate the safety ... specifically for the treatment of ruptured intracranial aneurysms.  Prof ... Bicetre University Hospital, in Paris, France ... the first patient. France ...
(Date:2/12/2016)... and SEOUL, South Korea ... Biosys­tems Menarini and Macrogen, Inc. today announced they ... and innovative procedures for precision medicine in cancer. ... Silicon Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput ... tests certified under the Clinical Laboratory Improvement Amendments ...
Breaking Medicine Technology: